In the present proposal we aim to study whether the intrauterine application of hyaloronic acid (Hyalobarrier ® Gel Endo) immediately after curettage, in patients with a recurrent curettage reduces the incidence and severity (ESGE score/…
ID
Bron
Verkorte titel
Aandoening
Approximately 15-20 % of all clinically recognized pregnancies in women of reproductive age will end in a
miscarriage. A possible complication of surgical treatment is intrauterine adhesion (IUA) formation or Asherman
syndrome. IUA can be asymptomatic but often results in symptoms. Recurrent curettage, defined as one or more
curettage in history, is a risk factor for IUA formation. Application of hyaluronic acid, a physical barrier has shown to be effective in prevention or reduction of adhesion formation in the uterine cavity. In the present protocol we propose to study whether intrauterine application of hyaloronic acid in patients undergoing a recurrent curettage because of a miscarriage could prevent or reduce the formation of intra-uterine adhesions.
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary outcome measure is number of patients with intra-uterine adhesions during the follow-up hysteroscopy.
Achtergrond van het onderzoek
Women with a miscarriage undergoing a recurrent curettage have an increased risk for adhesions formation. Adhesion formation is related with menstrual disturbances, fertility disorders and if pregnancy occurs it may be complicated. Prevention of adhesion formation is essential because of the possible serious implications. Application of hyaluronic acid has shown to prevent adhesion formation in the uterine cavity.
The hysteroscopic control offers the possibility to assess the presence of adhesions and the option to perform immediate adhesiolysis. Both are independent of the study arm and may therefore be beneficial to every patient included in the study.
Applications of hyaluronic acid has shown to be a safe procedure; no potential risk has been reported since it’s introduction. Potential risks of curettage are bleeding, perforation of the uterus wall, infection and induction of intra-uterine adhesions.
Additional, patients are asked to fill in questionnaires (approximately 15 questions) 3, 6 months and one year after the procedure.
Doel van het onderzoek
In the present proposal we aim to study whether the intrauterine application of hyaloronic acid (Hyalobarrier ® Gel Endo) immediately after curettage, in patients with a recurrent curettage reduces the incidence and severity (ESGE score/classification) of intra-uterine adhesions.
Onderzoeksopzet
01-11-2011: Start recruiting patients;
01-06-2013: Finishing study.
Onderzoeksproduct en/of interventie
Patients will be randomised and allocated to curettage with adhesion prevention (hyaloronic) group or curettage alone (control) group. Hyaloronic acid will be applied intrauterine once, immediately after curettage. A hysteroscopy is planned 8-12 weeks after the initial operation for identification of the adhesions and their extent in all patients.
Publiek
Jan Tooropstraat 164
A.B. Hooker
Amsterdam 1061 AE
The Netherlands
+31 (0)20 5108911
a.hooker@slaz.nl
Wetenschappelijk
Jan Tooropstraat 164
A.B. Hooker
Amsterdam 1061 AE
The Netherlands
+31 (0)20 5108911
a.hooker@slaz.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Consented patients, who had at least one previous suction or abrasive (blunt or sharp) curettage for a miscarriage in the history, visiting the outpatient clinic with a miscarriage and planned for curettage, will be included in the study. The ultrasound is a key in the diagnosis of miscarriage; at least one recent ultrasound examination (made within 7 days before randomisation) is required for inclusion. The maximum gestational age at inclusion is 14 weeks.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Patients with a suspected mola pregnancy;
2. Patients with a previous hysteroscopic surgery (endometrial ablation, removal of fibroids or surgical correction of congenital uterine anomalies);
3. Patients with contra-indications for one of the procedures at the time of randomisation;
4. Patients who do not master the Dutch or English language;
5. Patients who are younger than 18 years of age or mentally incompetent;
6. Patients with severe signs of infection (sepsis).
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2973 |
| NTR-old | NTR3120 |
| Ander register | METc VUmc : 2011/256 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |